Expertise in
4
conditions

Antonio Palumbo

Aviano, IT 
Expertise in
4
conditions
Aviano, IT 

Overview

Antonio Palumbo practices practicing medicine in Aviano, Italy.

Mr. Palumbo is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Agranulocytosis, Mantle Cell Lymphoma (MCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 267 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Aviano, Italy
Other Locations
Rome, Italy
Turin, Italy
Citta, Italy
Via Genova 3, Via, 10126, Italy
Brescia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Drugs: Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide, Dexamethasone
Study Phase: Phase 3
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
Enrollment Status: Completed
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Lenalidomide, Dexamethasone, Melphalan
Study Phase: Phase 3
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS
Enrollment Status: Completed
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drugs: Melphalan, Lenalidomide, Prednisone
Study Phase: Phase 3
A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients
A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: Velcade Subcutaneous Melphalan Prednisone, Velcade Cyclophosphamide Prednisone, Velcade Prednisone
Study Phase: Phase 2
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Pomalidomide, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide
A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Pomalidomide, Cyclophosphamide, Prednisone
Study Phase: Phase 1/Phase 2
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Revlimid and Prednisone followed by Revlimid, Melphalan and Prednisone
Study Phase: Phase 2
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

267 Total Publications

Loss of EMILIN-1/integrin axis drives microenvironmental reprogramming in gastric tumorigenesis.
Loss of EMILIN-1/integrin axis drives microenvironmental reprogramming in gastric tumorigenesis.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: January 19, 2026

Frequently Asked Questions about Antonio Palumbo

Is Antonio Palumbo a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Antonio Palumbo is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Antonio Palumbo participate in research or clinical trials?

Yes. Antonio Palumbo has published 267 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Antonio Palumbo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Palumbo's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile